AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 1.96 |
Market Cap | 87.89M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.33 |
PE Ratio (ttm) | -6.11 |
Forward PE | n/a |
Analyst | Strong Buy |
Ask | 2.06 |
Volume | 154,257 |
Avg. Volume (20D) | 189,140 |
Open | 2.00 |
Previous Close | 1.98 |
Day's Range | 1.96 - 2.06 |
52-Week Range | 1.81 - 4.93 |
Beta | undefined |
About HBIO
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgic...
Analyst Forecast
According to 2 analyst ratings, the average rating for HBIO stock is "Strong Buy." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.
Next Earnings Release
Analysts project revenue of $24.15M, reflecting a -14.22% YoY shrinking and earnings per share of 0.05, making a 25.00% increase YoY.
2 months ago · seekingalpha.com
Harvard Bioscience, Inc. (HBIO) Q3 2024 Earnings Call TranscriptHarvard Bioscience, Inc. (NASDAQ:HBIO ) Q3 2024 Results Conference Call November 7, 2024 8:00 AM ET Company Participants Kathryn Flynn - Corporate Controller James Green - Chairman, President and CEO ...